GlassScriptPhysician profile
Jaime Hayes
NPI 1710915574
$4,473.75
in general payments reported to CMS, 2019-2025
35 companies · $835 in 2025
The $835 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,071 · 2020: $32.64 · 2021: $99.31 · 2022: $421 · 2023: $728 · 2024: $1,287 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,850.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $820.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $437.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $398.13 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $368.42 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $284.19 | 2021-2025 | |
| Lilly USA, LLC | $272.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.79 | 2019-2025 | Xifaxan |
| Amgen INC. | $189.01 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $136.64 | 2023-2025 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $125.27 | 2022-2025 | |
| Glaxosmithkline, LLC. | $118.08 | 2022-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $115.84 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.35 | 2019-2022 | |
| Amarin Pharma, INC. | $103.07 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $93.89 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $89.72 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $57.08 | 2019-2024 | Veozah |
| Averitas Pharma INC. | $56.64 | 2023-2024 | Qutenza |
| Evoke Pharma, INC. | $52.90 | 2024-2025 | |
| Esperion Therapeutics, INC. | $40.13 | 2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $37.49 | 2022 | |
| Medtronic, INC. | $36.21 | 2024 | Closurefast |
| Sanofi-Aventis U.S. LLC | $35.82 | 2019 | |
| Jazz Pharmaceuticals INC. | $35.74 | 2019-2021 | |
| Acera Surgical, INC. | $28.26 | 2023 | Restrata Wound Matrix |
| Indivior INC. | $26.89 | 2024 | Sublocade |
| Qol Medical, LLC | $25.27 | 2025 | Sucraid |
| Vertex Pharmaceuticals Incorporated | $19.39 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.72 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.64 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2025 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $14.98 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.69 | 2022 | |
| Allergan, INC. | $13.56 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.